HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 321 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $380,263 | +33.0% | 6,683 | +2.8% | 0.03% | +3.8% |
Q2 2022 | $286,000 | +93.2% | 6,500 | +77.6% | 0.03% | +136.4% |
Q3 2021 | $148,000 | -41.3% | 3,660 | -34.1% | 0.01% | -45.0% |
Q2 2021 | $252,000 | -11.3% | 5,550 | -18.6% | 0.02% | -25.9% |
Q1 2021 | $284,000 | +0.7% | 6,816 | +3.1% | 0.03% | -6.9% |
Q4 2020 | $282,000 | +184.8% | 6,609 | +73.7% | 0.03% | +163.6% |
Q3 2020 | $99,000 | +230.0% | 3,805 | +232.0% | 0.01% | +175.0% |
Q2 2020 | $30,000 | +500.0% | 1,146 | +306.4% | 0.00% | +33.3% |
Q1 2020 | $5,000 | -88.9% | 282 | -89.0% | 0.00% | -25.0% |
Q4 2019 | $45,000 | +200.0% | 2,561 | +156.1% | 0.00% | +300.0% |
Q3 2019 | $15,000 | -44.4% | 1,000 | -37.5% | 0.00% | -66.7% |
Q2 2019 | $27,000 | -57.1% | 1,600 | -54.4% | 0.00% | -25.0% |
Q3 2018 | $63,000 | +117.2% | 3,510 | +59.5% | 0.00% | -20.0% |
Q3 2015 | $29,000 | -66.7% | 2,200 | -64.1% | 0.01% | -77.3% |
Q1 2015 | $87,000 | +200.0% | 6,124 | +102.0% | 0.02% | +340.0% |
Q2 2014 | $29,000 | – | 3,032 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |